1-15 of 15
Hiroaki Wakimoto
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CDKN2A/B Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition

Ali M. Nasser, Lisa Melamed, Ethan A. Wetzel, Jenny Chia-Chen Chang, Hiroaki Nagashima, Yosuke Kitagawa, Logan Muzyka, Hiroaki Wakimoto, Daniel P. Cahill, Julie J. Miller
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (14): 2996–3005.
https://doi.org/10.1158/1078-0432.CCR-24-0562
Published: 15 July 2024
View article titled, <em>CDKN2A/B</em> Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition
Open the PDF for <em>CDKN2A/B</em> Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition in another window
Includes: Supplementary data
Journal Articles

Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non–Small Cell Lung Cancer

Joshua K. Sabari, Vamsidhar Velcheti, Kazuhide Shimizu, Matthew R. Strickland, Rebecca S. Heist, Mohini Singh, Naema Nayyar, Anita Giobbie-Hurder, Subba R. Digumarthy, Justin F. Gainor, Anant P. Rajan, Edwin Nieblas-Bedolla, Aaron C. Burns, Jill Hallin, Peter Olson, James G. Christensen, Sylvia C. Kurz, Priscilla K. Brastianos, Hiroaki Wakimoto
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (15): 3318–3328.
https://doi.org/10.1158/1078-0432.CCR-22-0383
Published: 02 August 2022
View article titled, Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRAS<sup>G12C</sup>-Mutant Non–Small Cell Lung Cancer
Open the PDF for Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRAS<sup>G12C</sup>-Mutant Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in BRAFV600E-mutant High-grade Glioma

Jo Sasame, Naoki Ikegaya, Masahito Kawazu, Manabu Natsumeda, Takahiro Hayashi, Masataka Isoda, Kaishi Satomi, Arata Tomiyama, Akito Oshima, Hirokuni Honma, Yohei Miyake, Katsuhiro Takabayashi, Taishi Nakamura, Toshihide Ueno, Yuko Matsushita, Hiromichi Iwashita, Yu Kanemaru, Hidetoshi Murata, Akihide Ryo, Keita Terashima, Shoji Yamanaka, Yukihiko Fujii, Hiroyuki Mano, Takashi Komori, Koichi Ichimura, Daniel P. Cahill, Hiroaki Wakimoto, Tetsuya Yamamoto, Kensuke Tateishi
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (11): 2425–2439.
https://doi.org/10.1158/1078-0432.CCR-21-3622
Published: 01 June 2022
View article titled, HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in <em>BRAF<sup>V600E</sup></em>-mutant High-grade Glioma
Open the PDF for HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in <em>BRAF<sup>V600E</sup></em>-mutant High-grade Glioma in another window
Includes: Supplementary data
Journal Articles

Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma

Juri Kiyokawa, Yoichiro Kawamura, Shanawaz M. Ghouse, Simge Acar, Erinç Barçın, Jordi Martínez-Quintanilla, Robert L. Martuza, Ramon Alemany, Samuel D. Rabkin, Khalid Shah, Hiroaki Wakimoto
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (3): 889–902.
https://doi.org/10.1158/1078-0432.CCR-20-2400
Published: 01 February 2021
View article titled, Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma
Open the PDF for Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair

Fumi Higuchi, Hiroaki Nagashima, Jianfang Ning, Mara V.A. Koerner, Hiroaki Wakimoto, Daniel P. Cahill
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (7): 1690–1699.
https://doi.org/10.1158/1078-0432.CCR-19-2000
Published: 01 April 2020
View article titled, Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair
Open the PDF for Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair in another window
Includes: Supplementary data
Journal Articles

PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors

Kensuke Tateishi, Taishi Nakamura, Tareq A. Juratli, Erik A. Williams, Yuko Matsushita, Shigeta Miyake, Mayuko Nishi, Julie J. Miller, Shilpa S. Tummala, Alexandria L. Fink, Nina Lelic, Mara V.A. Koerner, Yohei Miyake, Jo Sasame, Kenji Fujimoto, Takahiro Tanaka, Ryogo Minamimoto, Shigeo Matsunaga, Shigeo Mukaihara, Takashi Shuto, Hiroki Taguchi, Naoko Udaka, Hidetoshi Murata, Akihide Ryo, Shoji Yamanaka, William T. Curry, Dora Dias-Santagata, Tetsuya Yamamoto, Koichi Ichimura, Tracy T. Batchelor, Andrew S. Chi, A. John Iafrate, Hiroaki Wakimoto, Daniel P. Cahill
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (14): 4375–4387.
https://doi.org/10.1158/1078-0432.CCR-18-4144
Published: 15 July 2019
View article titled, PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors
Open the PDF for PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors in another window
Includes: Supplementary data
Journal Articles

The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases

Franziska M. Ippen, Christopher A. Alvarez-Breckenridge, Benjamin M. Kuter, Alexandria L. Fink, Ivanna V. Bihun, Matthew Lastrapes, Tristan Penson, Stephen P. Schmidt, Gregory R. Wojtkiewicz, Jianfang Ning, Megha Subramanian, Anita Giobbie-Hurder, Maria Martinez-Lage, Scott L. Carter, Daniel P. Cahill, Hiroaki Wakimoto, Priscilla K. Brastianos
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (11): 3374–3383.
https://doi.org/10.1158/1078-0432.CCR-18-3049
Published: 03 June 2019
View article titled, The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in <em>PIK3CA</em>-Mutant Breast Cancer Brain Metastases
Open the PDF for The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in <em>PIK3CA</em>-Mutant Breast Cancer Brain Metastases in another window
Includes: Supplementary data
Journal Articles

Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase–mutant Glioma

Marissa Spino, Sylvia C. Kurz, Luis Chiriboga, Jonathan Serrano, Briana Zeck, Namita Sen, Seema Patel, Guomiao Shen, Varshini Vasudevaraja, Aristotelis Tsirigos, Carter M. Suryadevara, Joshua D. Frenster, Kensuke Tateishi, Hiroaki Wakimoto, Rajan Jain, Howard A. Riina, Theodore P. Nicolaides, Erik P. Sulman, Daniel P. Cahill, John G. Golfinos, Kumiko Isse, Laura R. Saunders, David Zagzag, Dimitris G. Placantonakis, Matija Snuderl, Andrew S. Chi
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (4): 1261–1271.
https://doi.org/10.1158/1078-0432.CCR-18-2312
Published: 15 February 2019
View article titled, Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase–mutant Glioma
Open the PDF for Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase–mutant Glioma in another window
Includes: Supplementary data
Journal Articles

Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models

Dipongkor Saha, Hiroaki Wakimoto, Cole W. Peters, Slawomir J. Antoszczyk, Samuel D. Rabkin, Robert L. Martuza
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (14): 3409–3422.
https://doi.org/10.1158/1078-0432.CCR-17-1717
Published: 15 July 2018
View article titled, Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models
Open the PDF for Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models in another window
Includes: Supplementary data
Journal Articles

Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma

Kensuke Tateishi, A. John Iafrate, Quan Ho, William T. Curry, Tracy T. Batchelor, Keith T. Flaherty, Maristela L. Onozato, Nina Lelic, Sudhandra Sundaram, Daniel P. Cahill, Andrew S. Chi, Hiroaki Wakimoto
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (17): 4452–4465.
https://doi.org/10.1158/1078-0432.CCR-15-2274
Published: 31 August 2016
View article titled, Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma
Open the PDF for Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH-Mutant Gliomas

Hiroaki Wakimoto, Shota Tanaka, William T. Curry, Franziska Loebel, Dan Zhao, Kensuke Tateishi, Juxiang Chen, Lindsay K. Klofas, Nina Lelic, James C. Kim, Dora Dias-Santagata, Leif W. Ellisen, Darrell R. Borger, Sarah-Maria Fendt, Matthew G. Vander Heiden, Tracy T. Batchelor, A. John Iafrate, Daniel P. Cahill, Andrew S. Chi
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (11): 2898–2909.
https://doi.org/10.1158/1078-0432.CCR-13-3052
Published: 29 May 2014
View article titled, Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in <em>IDH</em>-Mutant Gliomas
Open the PDF for Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in <em>IDH</em>-Mutant Gliomas in another window
Includes: Supplementary data
Journal Articles

Enhanced Antitumor Efficacy of Low-Dose Etoposide with Oncolytic Herpes Simplex Virus in Human Glioblastoma Stem Cell Xenografts

Tooba A. Cheema, Ryuichi Kanai, Geon Woo Kim, Hiroaki Wakimoto, Brent Passer, Samuel D. Rabkin, Robert L. Martuza
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (23): 7383–7393.
https://doi.org/10.1158/1078-0432.CCR-11-1762
Published: 30 November 2011
View article titled, Enhanced Antitumor Efficacy of Low-Dose Etoposide with Oncolytic Herpes Simplex Virus in Human Glioblastoma Stem Cell Xenografts
Open the PDF for Enhanced Antitumor Efficacy of Low-Dose Etoposide with Oncolytic Herpes Simplex Virus in Human Glioblastoma Stem Cell Xenografts in another window
Includes: Supplementary data
Journal Articles

A Novel Oncolytic Herpes Simplex Virus that Synergizes with Phosphoinositide 3-kinase/Akt Pathway Inhibitors to Target Glioblastoma Stem Cells

Ryuichi Kanai, Hiroaki Wakimoto, Robert L. Martuza, Samuel D. Rabkin
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (11): 3686–3696.
https://doi.org/10.1158/1078-0432.CCR-10-3142
Published: 01 June 2011
View article titled, A Novel Oncolytic Herpes Simplex Virus that Synergizes with Phosphoinositide 3-kinase/Akt Pathway Inhibitors to Target Glioblastoma Stem Cells
Open the PDF for A Novel Oncolytic Herpes Simplex Virus that Synergizes with Phosphoinositide 3-kinase/Akt Pathway Inhibitors to Target Glioblastoma Stem Cells in another window
Includes: Supplementary data
Journal Articles

Herpes Simplex Virus Us3(−) Mutant as Oncolytic Strategy and Synergizes with Phosphatidylinositol 3-Kinase-Akt–Targeting Molecular Therapeutics

Ta-Chiang Liu, Hiroaki Wakimoto, Robert L. Martuza, Samuel D. Rabkin
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (19): 5897–5902.
https://doi.org/10.1158/1078-0432.CCR-07-1013
Published: 01 October 2007
View article titled, Herpes Simplex Virus Us3(−) Mutant as Oncolytic Strategy and Synergizes with Phosphatidylinositol 3-Kinase-Akt–Targeting Molecular Therapeutics
Open the PDF for Herpes Simplex Virus Us3(−) Mutant as Oncolytic Strategy and Synergizes with Phosphatidylinositol 3-Kinase-Akt–Targeting Molecular Therapeutics in another window
Journal Articles

Impairment of Both Apoptotic and Cytoprotective Signalings in Glioma Cells Resistant to the Combined Use of Cisplatin and Tumor Necrosis Factor α

Lian Duan, Masaru Aoyagi, Masashi Tamaki, Yoshikazu Yoshino, Takashi Morimoto, Hiroaki Wakimoto, Yasuhiko Nagasaka, Kimiyoshi Hirakawa, Kikuo Ohno, Kiyotaka Yamamoto
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (1): 234–243.
https://doi.org/10.1158/1078-0432.CCR-1004-2
Published: 20 January 2004
View article titled, Impairment of Both Apoptotic and Cytoprotective Signalings in Glioma Cells Resistant to the Combined Use of Cisplatin and Tumor Necrosis Factor α
Open the PDF for Impairment of Both Apoptotic and Cytoprotective Signalings in Glioma Cells Resistant to the Combined Use of Cisplatin and Tumor Necrosis Factor α in another window